- Patients with migraine who received oral atogepant for 12 weeks had significantly fewer migraine days per month than those who received a placebo.
Why this matters
- Atogepant is delivered orally, offering a potential advantage over similar drugs currently available only by subcutaneous or intravenous injection.
- Double-blind, randomized, multicenter, phase 2b/3 trial.
- 825 patients with a history of migraine and 4-14 migraine days per month received placebo (n=186) or atogepant 10 mg once daily (n=93), 30 mg once daily (n=183), 60 mg once daily (n=186), 30 mg twice daily (n=86), or 60 mg twice daily (n=91).
- Funding: Allergan (before its acquisition by AbbVie).
- Significantly greater decreases in mean monthly migraine days in all atogepant groups compared with those receiving placebo (P=.039).
- All atogepant dosages were associated with significantly greater decreases in mean monthly headache days than placebo (P=.039).
- Significantly more patients reported ≥50% reduction in monthly migraine days in the 30-mg twice-daily (OR, 1.8; P=.034) and 60-mg twice-daily (OR, 2.0; P=.0097) groups compared with placebo.
- Significantly greater reduction in acute medication use in patients in the 30-mg twice-daily (−1.4 days; P=.034) and the 60-mg twice-daily group (−1.2; P=.0097) groups compared with placebo.
- Most common treatment-related adverse event was nausea.
- No long-term data.